Sign In
Buy CRVS
$11.60
-0.0900 (-0.770%)
At Close: Jun 03, 2026
U.S. RESEARCH ROUNDUP-Berkshire Hathaway, DHT Holdings, Novo Nordisk
06:06pm, Monday, 04'th May 2020
Wall Street securities analysts revised their ratings and price targets on several
U.S.-listed companies, including Berkshire Hathaway, DHT Holdings and Novo Nordisk, on Monday.
HIGHLIGHTS
Is Corvus Pharmaceuticals (NASDAQ:CRVS) In A Good Position To Invest In Growth?
11:26am, Monday, 04'th May 2020
We can readily understand why investors are attracted to unprofitable companies. For example, although...
Edited Transcript of CRVS earnings conference call or presentation 30-Apr-20 8:30pm GMT
06:51am, Sunday, 03'rd May 2020
Q1 2020 Corvus Pharmaceuticals Inc Earnings Call
Analysts Offer Insights on Healthcare Companies: Amarin (AMRN), Viking Therapeutics (VKTX) and Corvus Pharmaceuticals (CRVS)
11:17am, Friday, 01'st May 2020
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Amarin (AMRN), Viking Therapeutics (VKTX) and Corvus
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Amarin (
AMRN
–
Research Report
), Viking Therapeutics (
VKTX
–
Research Report
) and Corvus Pharma
Corvus Pharmaceuticals (CRVS) Receives a Buy from Mizuho Securities
02:29am, Friday, 01'st May 2020
Mizuho Securities analyst Mara Goldstein maintained a Buy rating on Corvus Pharmaceuticals (CRVS) yesterday and set a price target of $7.00. The company's
Corvus Pharmaceuticals (CRVS) Receives a Buy from Mizuho Securities
02:29am, Friday, 01'st May 2020
Mizuho Securities analyst
Mara Goldstein
maintained a
Buy
rating on Corvus Pharmaceuticals (
CRVS
–
Research Report
) yesterday and set a price target of
$7.00
. The company’s shares closed last T
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2020 Financial Results
08:05pm, Thursday, 30'th Apr 2020
Corvus Pharmaceuticals, Inc. (CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies and the utilization of novel b
The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Hologic To Launch Coronavirus Test, Amarin's Strong Q1
11:19am, Thursday, 30'th Apr 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 29)• Arvinas Inc (NASDAQ: ARVN) • Biondvax Pharmaceu
The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Hologic To Launch Coronavirus Test, Amarin's Strong Q1
12:00am, Thursday, 30'th Apr 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs April 29)
• Arvinas Inc (NASDAQ...
Mizuho Securities Sticks to Their Buy Rating for CytomX Therapeutics (CTMX)
09:05pm, Wednesday, 29'th Apr 2020
Mizuho Securities analyst Mara Goldstein reiterated a Buy rating on CytomX Therapeutics (CTMX) today and set a price target of $16.00. The company's
Mizuho Securities Sticks to Their Buy Rating for CytomX Therapeutics (CTMX)
09:05pm, Wednesday, 29'th Apr 2020
Mizuho Securities analyst Mara Goldstein reiterated a Buy rating on CytomX Therapeutics (CTMX – Research Report) today and set a
Fate Therapeutics (FATE) Gets a Buy Rating from Mizuho Securities
01:07pm, Wednesday, 29'th Apr 2020
Mizuho Securities analyst Mara Goldstein reiterated a Buy rating on Fate Therapeutics (FATE) today and set a price target of $40.00. The company's shares
Fate Therapeutics (FATE) Gets a Buy Rating from Mizuho Securities
01:07pm, Wednesday, 29'th Apr 2020
Mizuho Securities analyst Mara Goldstein reiterated a Buy rating on Fate Therapeutics (FATE – Research Report) today and set a
Mizuho Securities Sticks to Its Buy Rating for Merck & Company (MRK)
12:05pm, Tuesday, 28'th Apr 2020
Mizuho Securities analyst Mara Goldstein maintained a Buy rating on Merck & Company (MRK) today and set a price target of $100.00. The company's
